PeptideStack
5.2kquestions
20kanswers
220users

Is SURPASS-3 a fair comparison of cagrilintide against its comparator arm?

Asked 23 May 2024Modified 2.2 years agoViewed 21k times
15

Stated plainly: SURPASS-3 · cagrilintide.

This is asserted often enough that I assumed it was established, and then I went looking for the source.

I have searched the primary literature and found one paper that is adjacent but not on point.

Is there data behind this, or is it received wisdom?

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questionssemaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questionstirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
shareeditfollowflag
MV
askedmala_venkatesh21k2823 May 2024
3I tested this on two lots and got the same answer, so at least it reproduces. – Dr_Yusuf_Adeyemi 33 days ago
4The timing signature is the useful part. Everything else is confounded. – Dr_Sara_Kuusela 3 months ago
add a comment

No answers yet

This question has not been answered. It has been viewed 21k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.